The device, called a nomogram, works by measuring the levels of PSA in the patient’s blood. Researchers at Fox Chase recently found that they could accurately predict a patient’s risk of dying from prostate cancer by measuring the time between the last radiation treatment and biochemical failure.
Nomograms currently exist to help patients and physicians decide on a course of treatment, but this is the first kind to determine a patient’s death risk after receiving treatment.
Related Articles on Medical Devices:
GE’s New MRI Machine Gets FDA Approval
FDA Approves Gel to Temporarily Stop Blood Flow
FDA Clears Siemens’ Mobilett Mira Mobile Digital X-Ray System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
